

Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/230,955		
		Filing Date	February 04, 1999		
		First Named Inventor	Mason et al.		
		Group Art Unit	1642		
		Examiner Name	Brumback, B.		
Sheet	1	of	1	Attorney Docket Number	A-67653/RFT/AMS

COPY OF PAPERS FILED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Order Number	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
KAC	1	Epenetos et al., "Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours," The Lancet, November 06, 1982, 999-1004.
KAC	2	Epenetos, A.A., "Antibody guided lymphangiography in the staging of cervical cancer," Br. J. of Cancer, 51: 805-808 (1985).
KAC	3	Jha et al., "Monoclonal antibodies for the histopathological diagnosis of cervical neoplasia," British Journal of Obstetrics and Gynaecology, 91: 483-488 (1984).
KAC	4	Porta et al., "Diagnosis of cervical carcinoma using the monoclonal antibodies technique," Patologia Clinica Ostetrica e Ginecologia, 14: 348-355 (1986). (Translation)

RECEIVED
APR 12 2002
TECH CENTER 1600/2900

Examiner Signature	<i>Harvey J. Candella</i> <i>Heeda Fauriolak</i>	Date Considered	5/27/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.